Kyoto iCAP has completed a 200 million JPY investment in Link Therapeutics to advance the development of novel therapies targeting autoantibodies related to autoimmune diseases.
Investment Overview
The Kyoto University Innovation Capital Co., Ltd. (Kyoto iCAP), represented by its CEO, Mr. Kiminori Kusumi, has executed an additional investment of approximately 200 million JPY in Link Therapeutics Co., Ltd. (Link Tx), under the sponsorship of the Innovation Kyoto 2021 Fund. This funding is designated as a third-party allocation.
Link Tx, founded on the research of Assistant Professor Masahiro Shiokawa from Kyoto University's Graduate School of Medicine, focuses on biotech innovations. The company's mission is to elucidate the pathophysiological mechanisms of diseases related to autoantibodies and to create pioneering therapeutic methods targeting these autoantibodies.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Target Industry Overview
Link Tx's research primarily concentrates on a specific autoantibody related to patients with ulcerative colitis, namely the “anti-integrin αvβ6 autoantibody.” This focus facilitates the development of medical devices and pharmaceut
Similar Deals
Kyoto University Innovation Capital Co., Ltd. → Toregem Biopharma, Inc.
2024
京都大学イノベーションキャピタル株式会社
invested in
Link Therapeutics株式会社
in 2021
in a Series B deal
Disclosed details
Transaction Size: $9M